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Abstract: Leiomyoma is the most frequent benign monoclonal tumor (cells behave identically in culture) of the female 
reproductive system. It affected almost 50% of childbearing age women, deteriorating the quality of life and may cause 
infertility. The unique features of this pathology is the absence of detailed understanding of pathogenic mechanisms and 
continuous morbidity among any age groups. Despite the huge amount of articles and studies related to leiomyoma, 
review pretend to depict herein actual and non-trivial information. This review assemble a versatile description of med-
ical and biological aspects of leiomyomas. Explanation of genetic, molecular, pathophysiological mechanisms of uterine 
fibroid growing predetermine marked clinical symptoms of pathology. Mentioned model systems show multivariation 
of leiomyomas in human and animals. Review gives an opportunity analyze separate facets and collect it in one deep 
understanding of leiomyomas.
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Introduction
Uterine fibroids (correctly called leiomyomas or myomas) are monoclonal diploid highly 
frequent gynecological tumors that arise from the uterine smooth-muscle tissue and are 
characterized by the production of excessive quantities of extracellular matrix (ECM). Uterine 
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leiomyomata (UL) affects up to 80% of all women in their reproductive age. These benign 
tumors can develop into significantly sized lesions (from 10 mm to 20 cm). According to 
literature data, the youngest patient with LM was 19 years old, the oldest — 71. Majority 
cases are diagnosed between the ages of 28 and 52 years [1]. Histologically, they are neo-
plasms composed of disordered myometrium cells buried in abundant quantities of ECM, 
which formation also accounts for a substantial portion of tumor expression. Uterine fibroids 
are always benign [2, 3]. According to data from one survey, changes in fibroid size ranged 
from 89% shrinkage to 138% growth, with a median of 9% change in volume in a 6-month 
period. Moreover, fibroids can have growth spurts [4, 5]. 
Historical notes
The uterine leiomyoma has been known for human population since antique. Its first mention 
referred to Hippocrates as “uterine stones”, while Galen, in the second century of the Chris-
tian era, described the findings as “scleromas”. Moreover, some mummies, which exhibited 
in the English Museum in London, has calcified pelvic masses located though radiographic 
techniques which are suggestive of uterine leiomyoma [6]. 
Matthew Baillie, a Scottish physician and pathologist at St George’s Hospital in London, 
first described uterine leiomyomas in 1793. Rokitansky (1860) and Klob (1863) introduced 
the “fibroid” term, while Virchow, the famous German Pathologist, demonstrated that those 
tumors originated from the uterine smooth muscle. Thus, the term “myoma” became cur-
rent in clinical use [7]. 
The first laparotomy consequent to myoma indication was performed in 1809, in Danville, 
USA. On that occasion, the surgeon Ephraim McDowell operated Mrs. Jane Todd Crawford, 
a cousin of President Abraham Lincoln [6].
Prevalence
Assuredly, UL is the most common tumor among gynecological pathology. Different surveys 
and publications present own percentages of its prevalence and sometimes its data are con-
tradictory. Despite all, insist on majority of uterine fibroids among gynecological pathology. 
Tumors occur in 77% of women and has a slight difference between women with different 
skin color. Nearly 70% of white women and more than 80% of black women will have had 
at least one fibroid. Some studies prove this difference in a race by Vitamin D deficiency, 
naturally occurring in women with dark skin. However, this hypothesis is still discussible. 
In addition, black women have higher level of aromatase and elevated levels of estrogen in 
tissue. The prevalence of clinically significant fibroids peaks in the perimenopausal years and 
declines after menopause [8–11]. Interestingly, that growth rates also appear to be related 
to race. In the Fibroid Growth Study, white women had significantly lower UL growth rates 
as they approached menopause, whereas African American women’s growth rates remained 
unchanged [4]. 
The incidence of uterine fibroids in Poland is not precisely defined in fact, epidemio-
logical studies indicate a large variation of the results (from 20% to 40% of women) [12].
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Risk factors
Despite the high prevalence of UL, epidemiological studies on their frequency and risk 
factors are poorly [1]. 
An early onset of menarche (before the age of 10) mentioned as a risk factor of UL 
developing, whereas a menarche over the age of 16 seems to decline the same risk [13, 14]. 
The adipose tissue are one of aromatase’s source, where adrenal and ovarian androgens 
converts into estrogens. In fact, in UL tissue both enzymes, which convert androgens in es-
trogens (CYP19 aromatase and 17-β-hydroxysteroid dehydrogenase type I) are overexpressed 
[1, 15]. Obesity is an established risk factor for UL development. It can lead to increased 
producing of estrogens and decreased synthesis of sex hormone binding globulin [13]. Sur-
veys showed that adiponectin could inhibit leiomyoma growth in culture [16]. Moreover, the 
risk of UL increased in 21% with each 10 kg increase in body weight and with increasing 
body mass index [13]. 
The opposite effect has smoking. Several studies have revealed that nicotine inhibits 
aromatase. Smoking also impact on the 2-hydroxylation pathway of estradiol metabolism, 
which can lead to decline bioavailability of estrogen target tissues [13]. 
During pregnancy, leiomyomas are not inevitably growing. In most studies, the majority 
of leiomyomas remained the same size. Additionally, spontaneous shrinking was found in 
nearly 80% of women within 6 months of delivery [4]. 
Conflicting data coexist about the relationship between oral contraceptives (OC) and 
the growth of UL. This could be explained by the different content of estrogens and the type 
of progesterone in each specific OC preparation [13].
Coexistence of leiomyomata and others diseases were observed by many studies. According 
to published data, suggested that UL would cause hypertension as a consequence of urinary 
tract obstruction by large tumors. Moreover, inflammation process or infectious diseases 
can be associated with developing of some neoplasms. For instance, children infected with 
human immunodeficiency virus have increased incidence of both leiomyoma and leiomyo-
sarcoma in several organ [17]. Hyperinsulinemia is considered as a risk factor since insulin 
may influence UL development through direct promotion of myometrial smooth muscle cell 
proliferation or by increasing circulating levels of ovarian hormones [14]. 
Classification
Lack of a standardized nomenclature and classification makes communication difficult in 
clinical care and research. Traditionally classification of leiomyomas is based on the type of 
growth and location within the uterus [1]. 
There are four primary types of leiomyoma classified primarily by location in the uterus. 
— subserous (located just beneath the serosal surface);
— intramural (found primarily within the thick myometrium);
— submucous (located beneath the endometrium); 
— pedunculated (fibroids that grow on a small stalk that connects them to the inner or 
outer wall of the uterus).
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The most common is the intramural uterine leiomyoma. Moreover, the tumor can occur 
in the cervix (approximately 8% of cases) and their growth may proceeds towards the space 
between the layers of the broad ligament (intralaminar variant of leiomyoma). 
Fibroids can be single and multiple. If the uterus contains too many to count, it is re-
ferred to as diffuse uterine leiomyomatosis. In each location however multiple tumors are 
characterized by the presence of intratumoral septa [18].
Also, in clinical practice exist separate and detailed the European Society of Gyneco-
logical Endoscopy (ESGE) of submocous leiomyomas. It is can be useful when considering 
therapeutic options, including the surgical approach. The most widely used system catego-
rizes the leiomyomas into three subtypes according to the proportion of the lesion’s diam-
eter that is within the myometrium, usually as determined by saline infusion sonography 
(SIS) or hysteroscopy. The International Federation of Gynecology and Obstetrics (FIGO) 
uses the same system of classification of causes of abnormal uterine bleeding, but add some 
extra categories [19]. 
Pathogenesis
There are not exist one theory that may explain why UL are so common nowadays. Impor-
tantly consider in depth all biochemical pathways, genetic background, risk factors as triggers 
that leads to transformation normal myometrium in pathological focuses. 
ECM of fibroids is not only excessive in amount, but it is abnormally formed, and the 
components of such critical structural elements, such as the orientation of the fibrils and their 
length are altered in fibroids. Collagens are loosely packed and arranged in a nonparallel, 
disorganized manner. There is also greater remodeling of the ECM in UL as they express 
higher levels of specific metalloproteinases (MMPs) including MMP2 and MMP11 [20]. 
Myofibroblast cells produce collagen and others components of the ECM, but its inappro-
priate function to cause fibrosis. Some researchers suggested that the formation of fibrosis 
is mistaken in normal reparation, which periodically occur in the uterus. Leiomyoma and 
keloid have similar gene characteristics [8].
It had been proved by time and studies that the risk of leiomyomas uteri inherited. The 
first-degree relatives of affected women have a 2.5 times increased risk of developing fibroids. 
Mutations in genes, which encode cellular ferments, might be a reason of fibrotic phenotype of 
leiomyomas. SLK gene encoding STE20-like kinase, that expressed in proliferating myoblasts 
and is activated by epithelial disruption. This ferment play role in myogenic differentiation 
and cell motility. Activated by scratch wounding. A-kinase anchor protein-13 (AKAP13) is 
associated with cytoskeletal filaments in fibroid cells, which abnormally respond to mechanical 
stress and as a result – accompanied by abnormal extracellular matrix deposition [13, 21]. 
Moreover, frequently in patients with leiomyoma exist a series of mutations in mediator 
complex subunit 12 (MED12). It is a part of the mediator complex, which interacts with 
RNA polymerase II to regulate gene transcription, which often affected in leiomyomas and 
other mesenchyme tumors. MED12 interact with both types of estrogen receptors and in-
crease estrogen receptor function in vitro. It can explain the influence of estrogen on fibroid 
growth enhancement [21]. 
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Histology
The histologic phenotype of LM always different from the adjacent normal myometrium. 
Most leyomyomata demonstrate much more extracellular matrix deposition than normal 
myometrium does, and present as encapsulated collagen-rich masses of smooth muscle 
cells. LM typically have 50% more collagen than normal myometrium and an increased 
proportion of type I collagen [1]. Another sources revealed that collagen of type III in 
LM tissue is highly deposed too [20]. Uterine leiomyomas are usually well-circumscribed 
tumors.
According to the 4th edition of World Health Organization Classification of tumors 
(Tumors of the Breast and Female genital organs), histologically, leiomyomas are benign 
neoplasms composed of disorder smooth-muscle cells buried in abundant quantities of 
extracellular matrix. This pathology is accompanied by changing of myometrial structure 
and cellular morphology. It were described two types of UL: poor in vessels and rich in 
vessels.
Grossly, this pathology is multiple, have spherical form, also firm and pale. On section 
leiomyoma’s surface is white to tan in color, with a whorled trabecular texture. This benign 
tumor cause deformation of surrounding tissues, often with degenerative changes [22].
Microscopically, leiomyomas have whorled, anastomosing fascicles of uni- and fusiform 
cells. Typically, cells have spindle form, abundant fibrillar, eosinophilic cytoplasm and indis-
tinct borders. Sometimes, particularly in cellular leiomyomas, the cytoplasm is sparse, and 
the fascicular arrangement of the cells may be muted. Nuclei with small nucleoli and finely 
dispersed chromatin. Nearby myometrium is less cellular than closed located leiomyomas [3].
Depends on location and size, can be ulcerated, hemorrhagic, with necrotic and cystic 
degeneration, sometimes become calcified. Hyaline fibrosis, edema and, on occasion, marked 
hydric change can be present. Haemorrhage, necrosis, oedema, myxoid change, hypercellular 
foci and cellular hypertrophy occur in leiomyomas in women who are pregnant or taking 
progestins [23, 24].
In addition, several histological variants of leiomyoma uterus are exist: mitotically active, 
cellular, haemorrhagic cellular (or “apoplectic”), epitheloid, myxoid, atypical (pleomorphic, 
bizarre or symplastic) and lipoleiomyoma. Each of them has own characteristics and progno-
sis. Growth pattern variants may produce unusual clinical, macroscopic and/or histological 
features. There are four types of growth pattern: diffuse leiomyomatosis, dissecting leiomy-
oma, intravenous leiomyomatosis and benign metastasizing leiomyoma. 
Vascular structure 
Uterine fibroids contain their own specific vasculature. Usually following age of 50 uterine 
arteries are narrowed or even sometimes closed by atherosclerotic obliteration [25]. Vascular 
architecture is investigated by classical dye-injection methods, as well as by corrosion casting 
combined with scanning electron microscopy [26]. 
A unique feature of larger UL is “vascular capsule”, which characterized by an extremely 
dense vascular network at the border between the tumor and the surrounding myometrium, 
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often separated from the unchanged myometrium by a narrow avascular cleft. The smallest 
leimyomata are usually avascular. Middle size tumors usually have well-developed vascular 
capsule and could be occasionally traversed by small vessels (arteries and veins). Large my-
omata (> 1cm) contain a chaotic network of blood vessels — mostly capillaries, arterioles 
and venules [18, 26].
Walocha et al. distinguished two types of vascularization of intramural UL: a type where 
peripheral vessels form relatively dense vascular capsule, while the center of the lesion seems 
to be poorly vascularized and type two, where foci of intensive regression of tumor are sep-
arated by strong vascular septa [18, 27].
Genetic
The majority of UL (60%) are chromosomally normal and the remainder share similar tu-
mor-specific abnormalities [2]. Chromosomally abnormal tumors are usually larger and a 
greater percentage of cytogenetically abnormal fibroids are located submucosally [2, 21]. 
Genetic changes confined to the tumor tissue and lacking in adjacent myometrial tissue 
offer a highly valuable tool to shed light on the molecular pathogenesis of the disease. The 
variety of chromosomal rearrangements, including but not limited to translocation, deletion 
and trisomy, predict different molecular genetic mechanisms for UL formation and growth 
[28]. The abnormal karyotypes in leiomyoma were frequently accompanied by 46, XX, i.e., 
cytogenetically normal female cells [14]. 
Global gene expression profile of LM revealed that hundreds of genes are deregulated 
and caused changing in cell proliferation, differentiation and extracellular matrix production 
[14]. The most often leiomyomas have such genetic abnormalities as deletion of portions of 
7q, trisomy 12, rearrangements of 12q15, 6p21 or 10q22. Additional abnormalities, which 
appear consistently but not as frequently, include rearrangements of chromosomes X, 1, 3 
and 13 [28]. The variety of rearrangements suggests that there is more than one molecular 
pathway leading to leiomyoma tumorogenesis [29].
Few studies showed a positive correlation between the presence of a cytogenetic abnor-
mality and the anatomic location of LM: intramural (35%), subserous (29%) and submucous 
(12%) type [14, 30]. Analyses of multiple leiomyomas from a single uterus have demonstrated 
that the tumors can harbor different chromosomal changes and suggest that each tumor can 
develop independently [14]. 
One of the most common subgroups is characterized by rearrangement of 12q14-15, 
typically as a t(12;14)(q14-15;q23-24), which occurs in approximately 7.5% of all leiomyomas 
and 20% of karyotypically abnormal leiomyomas [8, 31]. Most of the 12q15 breakpoints are 
located upstream of the HMGA2 gene promoter, giving rise to full-length HMGA2 overex-
pression [8]. The presence of t(12;14) has been associated with larger sized UL than those 
with either normal karyotypes or interstitial 7q22 deletions [14, 28, 30, 31].
One of the largest UL subgroups is defined by the presence of chromosome 7 long arm 
abnormalities, most commonly the interstitial deletion del(7)(q22q32), which represents 
approximately 15% of all UL and 20–35% of karyotypically abnormal UL. It is notable that 
UL with 7q abnormalities are often mosaic with karyotypically normal 46,XX cells and when 
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cultured grow poorly and frequently lose the chromosomally aberrant cell line [21]. Tumors 
with del(7) were found to be smaller and those with mosaic karyotypes were intermediate 
in size [14, 32]. In addition, del(7) may be associated with t(12;14) or t(1;6), suggesting in-
volvement of del(7) in the karyotypic evolution of leiomyoma [14].
Rearrangements of 6 chromosome in band 21 in leiomyoma occur with a frequency of 
5% and include t(1;6)(q23;p21), t(6;14)(p21;q24), and t(6;10) (p21;q22), as well as inversions 
and translocations with other chromosomes [14].
About 5% of chromosomally abnormal uterine leiomyomata had rearrangements of 10q22 
[29]. This region is implicated in a wide variety of tumors, with a number of tumor suppres-
sor genes including PTEN/MMAC1 (at 10q23.3) and DMBT1 (at 10q25.3-q26.1) [1, 14].
Genetic studies of uterine leiomyomas from a variety of populations have demonstrated 
translocations in the high mobility group (HMG) protein genes, specifically HMGA1 and 
HMGA2. Aberrant expression of HMGA2 may affect the expression of growth factors and 
growth inhibitors, fibroblast growth factor 2 (FGF2) and p19 alternate reading frame (p19Arf), 
respectively.  Moreover, the overexpression of HMGA2 in leiomyomas correlates with in-
creased FGF2 levels and tumor size, and repression of the growth inhibitor factor p19Arf [16].
There is also a genomewide difference in DNA methylation between the fibroid tissue 
and the adjacent normal myometrium. Promoter methylation-mediated gene silencing might 
be involved in pathogenesis of leiomyomas [8, 13]. 
As expression and deposition of ECM and collagens are common for leiomyomata, will 
be important note some facts about its gene regulation. Studies were found significant dif-
ferential expression of dermatopontin (DPT) and various isoforms of the fibrillar (I, III, V) 
and nonfibrillar collagen genes (IV and VI) in leiomoyoma compared to myometrium [33]. 
Hereditary syndromes
UL may be a component of several hereditary syndromes. For instance, hereditary leiomy-
omatosis and renal cell cancer syndrome (HLRCC) is an autosomal dominant disease (also 
known as Reed’s syndrome), characterized by aggressive early-onset renal cancer combined 
with multiple leiomyomas of skin and uterus. Patients with HLRCC have a deficiency of the 
fumarate hydratase. About 77 percent women with this syndrome have uterine leiomyomas, 
that early appears and are multiple with size ranging from 1 to 8 cm. Also, they are usually 
highly symptomatic. Histologically, these tumors oftentimes have increased cellularity and 
nuclear atypia. Usually, patients with HLRCC have cellular or atypical variants of leiomyo-
mas [2, 4, 24, 34–36].
Alport syndrome, caused progressive nephropathy and connected with a defect in CO-
L4A5 and COL4A6 genes, include rare clinical condition — diffuse leiomyomatosis. It’s 
characterized by benign smooth-muscle cell proliferation in the female genital tract. Diffuse 
leiomyomatosis concerns approximately 5% of patients with Alport syndrome [2].
One more example of combination leiomyomas with hereditary syndromes is Reckling-
hausen’s disease (Neurofibromatosis type 1 (NF1)). It is one of the most frequent human 
genetic diseases, with a prevalence of one case in 3,000 births. The literature suggests that 
the association of NF1 and leiomyomas or leiomyosarcoma is not entirely coincidental [37].
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Growth factors
Many uterine growth factors are regulated by sex steroids, which effect through local mod-
ulation of growth factors, cytokines and chemokines. The autocrine/paracrine signaling 
plays an important role in the events involved in myometrium cellular transformation and 
turnover that are involved in leiomyoma pathophysiology [21, 22].
 Recently proved that several growth factors and their respective receptors seem to play 
a role in leiomyoma growth. The main of them are: inslulin-like growth factors (IGFs), plate-
let-derived growth factor (PDGF), vascular endothelial growth factor (VRGF), epidermal 
growth factor (EGF) and basic fibroblast growth factor (bFGF), heparin binding epidermal 
growth factor (HB-EGF), tumor necrosis factor-α (TGF-α), transforming growth factor beta 
(TGF-β), acidic fibroblast growth factor (aFGF) and adrenomedullin (ADM). Some of them 
involved in angiogenesis in leiomyoma, others can modulate the rate of cell proliferation 
or regulate gene expression. For instance, TGF-β is a potent promoter of connective tissue 
formation [1, 8, 21, 22, 38]. 
PDGF modulate the rate of cell proliferation in myometrium and leiomyoma cells and 
probably play a role in SMC hypertrophy as its expression is increased in myometrium during 
gestation, while decreasing of PDGF associated with shrinkage of uterine volume [1, 13]. Also, 
this growth factor is upregulated by estrogen in uterine SMC and downregulted by GnRH 
agonists. PDGF may interacts with other growth factors such as TGFβ and EGF to enhance 
proliferation [22]. EGF and PDGF seem to increase DNA synthesis and polyploidization in 
leiomyoma cells through transient activation of kinase pathways [7, 13].
bFGF mRNA and protein are present in myometrial and leiomyoma smooth muscle 
cells, with higher level in leiomyoma cells. Leiomyoma tissue has an extensive ECM with 
heparin sulfate proteoglycans that serves as a reservoir for bFGF. Several researchers report-
ed the expression of bFGF and its receptors FGFR-1 and FGFR-2 in both leiomyoma and 
leiomyoma cells, with more distinct expression of FGFR-1 in the tumors compared with 
myometrium [21, 22].
HB-EGF is a strong mitogen for both fibroblasts and smooth muscle cells. Shows a de-
creased expression in leiomyomas relative to normal myometrium. Progesterone increase 
its expression in the uterine stroma and decreases in luminal and glandular epithelium. 
Estradiol increases HB-EGF in epithelial cells and has no effect on stromal cells. mRNA 
and protein amounts are lower in leiomyoma smooth muscle cells compared with normal 
myometrium [20, 21].
No differences in VEFG protein expression have been detected between normal myo-
metrium and leiomyoma tissue. Another studies revealed a stronger VEGF expression was 
found in leiomyomas than in adjacent myometrium, indicating the local angiogenesis may 
be important for the development and growth of tumor tissue. Interestingly, that VEGF is 
significantly expressed in leiomyosarcoma compared with leiomyoma [21, 22]. 
Recently has been demonstrated that EGF plays a crucial role as a local growth factor 
in regulating leiomyoma growth. EGF and EGF receptor mRNA are both highly expressed 
in normal myometrium and leiomyoma smooth muscle cells. The level of EGF mRNA is 
higher in leiomyomata during the secretory phase. Progesterone increases EGF expression 
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and mitogenesis of cultured smooth muscle cells. Were found that asoprisnil (J867), a novel 
selective P4 receptor (PR) modulator down-regulated expression of EGF and its receptors in 
cultured uterine leiomyoma cells without altering EGF-induced proliferation and apoptosis 
rates in normal myometrium. Estrogen treatment reduces EGF expression but upregulates the 
expression of EGF-R and proliferative cell nuclear antigen (PCNA), an endogenous marker 
of cell proliferation, in both myometrium and leiomyoma cells [22].
TGF-β and its receptors are expressed in human myometrium and leiomyomas. Their 
role on leiomyoma pathogenesis has been hypothesized because TGF-βs, their receptors and 
downstream signaling mediators are overexpressed in UL compared with normal myometri-
um. Leiomyomas express up to six fold higher levels of mRNA for TGF-β3 than do normal 
myometrial cells at all stages of the menstrual cycle [14]. When TGF-β is downregulated, 
the mRNA expression of multiple ECM genes in tumor is decline [13, 22].
Some studies reveal that IGFs and their signaling pathways are activated in approximately 
one third of fibroids and that IGF signaling is positively associated with large and actively 
growing fibroids. They regulate cell proliferation, differentiation and apoptosis. There are 
two IGFs: IGF-1 and IGF-2.Over-expression of IGF-2 in LM has been identified in many 
independent global gene profiling analysis. Although IGF-1 transcription can be promoted 
by estrogen in both normal and tumor tissue, only a portion of fibroids (about one third) 
have its increased level (particularly in large LM) [22, 38].
Adrenomedullin belongs to the calcitonin superfamily of peptides that includes calci-
tonin, calcitonin gene-related peptide (CGRP) and amilyn. This substance manifests as an 
inhibitor of apoptosis and an autocrine growth factor in several human cancer cell lines and 
endometrium. The ADM is an important angiogenic factor in smooth muscle tumor of uter-
us. ADM protein expression has been reported in both myometrium and leiomyoma tissue, 
where it is significantly higher. Although, it can be used as an accessory marker in estimat-
ing the malignant potency of UL and judging the prognosis of uterine leiomyosarcomas, 
and as a novel molecular target of anti-angiogenic and anticarcinogenic strategies [21, 39]. 
Among the angiogenic factors, bFGF and AMD are the likely candidates to promote 
angiogenesis around myomata, since they were found to occur in larger quantities in myo-
mata than in the unchanged myomatrial areas [26].
Hormones and its receptors
Numerous experiments have shown that combination of estrogen and progesterone promote 
myometrial and leiomyoma smooth muscle cells growth. They regulate most of genes that 
encode growth factors. 
UL growth is related to estrogens and their receptors. Estrogen receptors consist of ERα 
and ERβ. Leiomyomata and myometrium expressed both types of receptors. Several stud-
ies found that mRNA and protein expression levels are higher in leiomyomara compare to 
those in normal myometrium [13]. Different studies present dual judgment about expression 
of both types of estrogen receptors in leiomyomas. One of them demonstrate significantly 
higher expression of ERα as compared of ERβ in the tumor. Others show opposite results 
and justified possible involvement expression ratio in the growth potential of leiomyomas. 
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Estrogens can regulate the expression of growth factors by acting some signaling pathways. 
They upregulate PDGF expression in fibroid cells and downregulate EGF expression, while 
upregulate the expression of EGF-R in both myometrium and leiomyoma cells [7].
Progesterone and its receptors are essential for cell proliferation, the accumulation of 
extracellular matrix, and cellular hypertrophy. Their expression (PR-A and PR-B) is signifi-
cantly higher in leiomyoma tissue compared with normal myometrium. Progesterone has an 
impact on some growth factors. It upregulates the EGF (mitogenic) and TGF-β3 (bimodal 
action) expression. Likewise, it seems to downregulate IGF-I expression. Hypothetically, 
progesterone could stimulate leiomyoma cell growth through upregulating B-cell lymphoma 
2 (Bcl-2) protein expression and downregulating TNF-α expression [13]. 
Human uterine leiomyomata express higher levels of peroxisome proliferator-activated 
receptor γ, retinoid X, and all-trans retinoic acid than myometrium [40]. 
Cytokines and chemokines
The expression of many cytokines is also regulated by ovarian steroids. Among the major 
cytokines the expression of IL-1, IL-6, IL-11, IL-12, IL-15, IFNγ, TNF- α, CM-CSF, and 
erythropoietin has been documented in UL, with limited evidence of their biological in-
volvement in leiomyoma pathophysiology [1]. However, IL-11 and IL-13 similar to TGF-β, 
are overexpressed in leiomyomata, and differentially regulated by estrogen, progesterone, 
GnRHa, and TGF-β. Chemokines and their receptors (MIP-1α, MIP-1β, RANTES, eotax-
in, eotaxin-2, IL-8, CCR1, CCR3, CCR5, CXCR1 and CXCR2 mRNA) are also play role in 
pathogenesis of leiomyoma. Leiomyoma tissue has a lack of IL-8, IL-8, MCP-1 and MCP-2 
compare with normal myometrium [13].
Model systems
Researchers may studying in details mechanisms underlying UL growth regulation and oth-
ers features by creating artificial models (human and animals). Had been distinguish three 
types of models: in vitro, in vivo and stem cells models. In vitro were created such systems 
as human uterine leiomyoma cells (2008, 2010, 2012), Htert-human uterine leiomyoma cells 
(2012), 3D in vitro model (2012) and Eker leiomyoma tumor-derived (ELT) 3 cells (2010). 
Wider range of models in vivo are presented and they are mostly animals: Eker rat (2009, 
2011), Guinea pig (1989), Miniature pet pigs (2010), Pot bellied pig (2004), Japanese quail 
(2009), CD-1 mice (2002), Calcium-binding protein (CaBP) 9K/TagJ transgenic mice (1996), 
Transplanted fibroid cells in mice (xenografts) (2009, 2010), Immunodeficient (NOD/SCID/
gammac(null): NOG) mice (2010), Adenovirus-enhanced human fibroid explants (2008) 
and Beta-catenin mice (2009). Two stem cells systems available for modeling of pathologi-
cal condition: Human uterine leiomyomas (2010) and Leiomyoma-derived side population 
(LMSP) stem/reservoir cells (2012) [11, 16].
The most widely used is Eker rat model in which approximately 65% of female Tsc2Ek/+ 
carriers develop leiomyomas, a frequency similar to that seen in women. This model has 
similar phenotypic, biochemical, hormonal and genetic characteristics compare with cognate 
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human pathology. Approximately 8% of aged guinea pigs develop spontaneous leiomyomas, 
and ovariectomy in young animals combined with high-dose estrogen supplementation 
causes the development of uterine and abdominal leiomyomas with a high frequency. Both 
models have a common result, which suggest that selective estrogen modulators and per-
oxisome proliferator-activator receptors ligands may be effective as therapeutic agents [11].
A xenograft model showed that removal of steroid hormones associate with decreasing 
tumor size and reducing cell size. Moreover, it proved depending of progesterone receptors 
form estrogen in UL [16].
Symptoms
The majority of women with UL are asymptomatic, consequently get less clinical attention 
and fibroid tumors often remain undiagnosed [41]. Prevalence in symptom-free women has 
been reported to be as low as 7.8% in Scandinavian women aged 33 to 40, whereas in the 
United States it is almost 40% in white patients and more than 60% in women of African 
ancestry in the same age group [19]. Symptoms are often depends on size, localization and 
numbers of fibroids. The clinical presentation can be divided into three main groups of 
symptoms: abnormal bleeding, pressure/pain, and reproductive problems.
Usually leiomyomata are often highly vascularized (especially in the pseudocapsule) and 
frequently associated with menorrhagia. One study revealed that 30% of the patients had 
this complication. The range varied from 17 to 62%. After menorrhagia, the most common 
abnormal bleeding symptom is prolonged vaginal bleeding. Usually it is occur during sub-
mocous leiomyoma because fibroid destroy the endometrial cavity [1]. 
As leiomyoma is tissue which can growing outside, it can mechanically push on sur-
rounding organs and nerves, accompanying by subjective feeling of heaviness, pressure, or 
dull ache but rarely pain. The size and localization of UL may affect the pressure and pain 
experienced. Frequently, these symptoms combine with others and create a complex of dis-
orders. Anterior leiomyomata may cause urinary symptoms, while posterior — constipation. 
Occasionally acute pain may be associated with leiomyomata. In addition, pain can be a 
symptom of fibroid degeneration (usually necrosis). In literature, present data of one study 
depict that 42% of women with chronic pain requiring laparoscopy had leiomyomata [1, 8].
Leiomyoma can be a reason of infertility. The incidence of UL in women with unexplained 
infertility is estimated to be 1 to 2.4%. It can be caused by distortion of the endometrial 
cavity, obstruction of uterine tubes or cervix, alteration of endometrium, vascular changes 
which discommode to implantation. Moreover, submucous fibroids seems to be a reason 
of infertility. They are accompanied by decreasing of markers of endometrial receptivity 
(HOXA10, HOXA11 and BTEB1) and lower concentrations of glycodelin and interleukin 
10 in mid-luteal phase in the endometrium [42]. Likewise, leiomyoma may interfere with 
sperm migration and embryo transport by modifying the normal uterine contractility [43].
Subserous and submucosal fibroids slightly increased the risk of pre-term birth. The 
majority of women with uterine fibroids will have normal pregnancy outcomes [16].
Sarcomatous change in leiomyomata is rare and it thought to occur in no more than 
0.1% of leiomyomata. It is more common in postmenopausal women and can present with 
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bleeding or pain associated with uterine enlargement. Sometimes single cases with hypothesis 
of cancer transformation of UL are published, but they are still discussable [1]. 
Diagnosis
In general, patients with leiomyoma will come to doctor with complaints of abnormal bleeding 
or infertility. The diagnosis can include vaginal examination, ultrasound, hysteroscopy and 
magnetic resonance imaging (MRI). Clinical examination is accurate with a uterine size of 
12 weeks (correlating with a uterine weight of approximately 300 g) or larger. Ultrasonog-
raphy is helpful to observe size, localization, numbers, structure, relation to the endometrial 
cavity of fibroid and assess the adnexa if these can’t be palpated separately with confidence 
[44]. Moreover, it may be essential in differential diagnosis between several gynecological 
pathologies, which might be suspected. For instance, some parameters of blood flow imped-
ance of arteries within or around the uterine lesions revealed a consistent and significant 
difference between leiomyoma and adenomyosis, made by Doppler [1, 45].
Treatment
Symptoms that negatively affect a woman’s daily life are a primary indication for treatment. 
Standard treatments of LM symptoms include myomectomy, hysterectomy, uterine artery 
embolization, and pharmacologic treatments that reduce symptoms. 
Myomectomy has been the mainstay for women who wish to preserve their fertility. It 
can be done by laparotomy or laparoscopy. Vaginal myomectomy is the classical method for 
cervical leyimyomata and pedunculated submucosal UL. Hysterectomy can be carried out 
abdominally, vaginally, or laparoscopically. A large-scale surveys have shown that 70–80% 
of hysterectomies are performed by the abdominal approach, especially in the case of uter-
ine leiomyomata [1].
For patients with asymptomatic uterine myomas, surgery was determined in which 1) the 
size of tumor was bigger than 6 cm, 2) if a request was made by a patient with cancer phobia, 
and 3) a surgeon determined to do so [46].
Uterine artery embolization (UAE) has proven to be a well-tolerated, minimally inva-
sive treatment for symptomatic uterine fibroids. Its aim is the reduction or elimination of 
fibroid-related symptoms, but not the removal of the leiomyoma. However, it also accom-
plishes a reduction of the size of the fibroid. A symptomatic uterine fibroid is an indication 
for uterine artery embolization. 
Outcome
Study, provided in USA in 2010, compare different kinds of surgical treatment in cases of 
leiomyoma and its outcomes. The frequency of adverse events was similar among the groups 
(6.7% of uterine artery embolization, 13.3% of myomectomy, and 13.3% of hysterectomy) [47].
Another study observe patients with LM and infertility (primary and secondary) after 
surgical treatment. Pregnancy outcome confirmed the validity of the laparoscopic approach. 
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Approximately 55% of the infertile women who underwent surgery achieved pregnancy. The 
reappearance of UL during the follow-up period was similar in the two groups (22.3% after 
laparotomy; 21.4% after laparoscopy) and, considering only large leiomyomata, the recur-
rence rates were 6.7% (laparotomy) and 1.8% (laparoscopy) respectively [43].
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